Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

Theranostics 2021; 11(11):5174-5196. doi:10.7150/thno.56471 This issue Cite

Review

Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis

Tao Wang1,2*, Lanmei Chen1,3*, Arpitha Chikkanna1, Suxiang Chen1, Isabell Brusius1, Nabayet Sbuh1, Rakesh N. Veedu1,2✉

1. Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth 6150, Australia.
2. Perron Institute for Neurological and Translational Science, Perth 6009, Australia.
3. Guangdong Key Laboratory for Research and Development of Nature Drugs, School of Pharmacy, Guangdong Medical University, Zhanjiang 524023, China.
* These authors contributed equally.

✉ Corresponding author: R.Veeduedu.au; Tel.: +61 8 9360 2803

Citation:
Wang T, Chen L, Chikkanna A, Chen S, Brusius I, Sbuh N, Veedu RN. Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis. Theranostics 2021; 11(11):5174-5196. doi:10.7150/thno.56471. https://www.thno.org/v11p5174.htm
Other styles

File import instruction

Abstract

Graphic abstract

Lateral flow assay (LFA) has made a paradigm shift in the in vitro diagnosis field due to its rapid turnaround time, ease of operation and exceptional affordability. Currently used LFAs predominantly use antibodies. However, the high inter-batch variations, error margin and storage requirements of the conventional antibody-based LFAs significantly impede its applications. The recent progress in aptamer technology provides an opportunity to combine the potential of aptamer and LFA towards building a promising platform for highly efficient point-of-care device development. Over the past decades, different forms of aptamer-based LFAs have been introduced for broad applications ranging from disease diagnosis, agricultural industry to environmental sciences, especially for the detection of antibody-inaccessible small molecules such as toxins and heavy metals. But commercial aptamer-based LFAs are still not used widely compared with antibodies. In this work, by analysing the key issues of aptamer-based LFA design, including immobilization strategies, signalling methods, and target capturing approaches, we provide a comprehensive overview about aptamer-based LFA design strategies to facilitate researchers to develop optimised aptamer-based LFAs.

Keywords: Aptamer, lateral flow assay, point-of-care, biosensor, sandwich assay, competitive assay.

Citation styles

APA
Wang, T., Chen, L., Chikkanna, A., Chen, S., Brusius, I., Sbuh, N., Veedu, R.N. (2021). Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis. Theranostics, 11(11), 5174-5196. https://doi.org/10.7150/thno.56471.

ACS
Wang, T.; Chen, L.; Chikkanna, A.; Chen, S.; Brusius, I.; Sbuh, N.; Veedu, R.N. Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis. Theranostics 2021, 11 (11), 5174-5196. DOI: 10.7150/thno.56471.

NLM
Wang T, Chen L, Chikkanna A, Chen S, Brusius I, Sbuh N, Veedu RN. Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis. Theranostics 2021; 11(11):5174-5196. doi:10.7150/thno.56471. https://www.thno.org/v11p5174.htm

CSE
Wang T, Chen L, Chikkanna A, Chen S, Brusius I, Sbuh N, Veedu RN. 2021. Development of nucleic acid aptamer-based lateral flow assays: A robust platform for cost-effective point-of-care diagnosis. Theranostics. 11(11):5174-5196.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use